1. Background {#sec105300}
=============

Cocaine use can cause acute or chronic toxicity. This drug is responsible for approximately 5% to 10% of emergency department visits in the United States and it is also one of the most frequent causes of drug-related deaths ([@A18780R1]-[@A18780R4]). Cocaine is associated with many health complications that affect neurological, cardiovascular and gastrointestinal systems.

Cocaine increases the activity of dopamine, norepinephrine and serotonin, and in turn blocks the reuptake transporters for these monoamines in the central and peripheral nervous systems. In addition, cocaine modulates the endogenous opiate system. Acute cocaine poisoning causes neuronal hyperexcitability and can be fatal ([@A18780R3]). The current treatment of choice for acute cocaine poisoning is the use of benzodiazepines ([@A18780R1]), yet they do not directly interact with any of these neurotransmitter systems. Alpha 2 adrenoceptor (α2-AR) agonists may decrease the proportion of subjects reaching the end point of irreversible toxicity and may prolong survival after cocaine poisoning.

Central sympatholytic drugs, particularly α2-AR agonists such as alpha-methyldopa, have been shown to reverse cocaine-induced increase in blood pressure and vascular resistance in experimental animals ([@A18780R5]). Dexmedetomidine has clinically relevant sedative and analgesic properties and it is a highly selective α2-AR agonist. Although its precise mechanisms are unclear, recent studies have suggested that α2-AR agonists have effects not only on noradrenergic systems but also on dopaminergic neurotransmitters as well ([@A18780R6]-[@A18780R8]). Certain areas of the brain, such as the nucleus accumbens (NAcc) (which is a mesolimbic dopaminergic area), are known to be terminal projection sites for both noradrenergic and dopaminergic neurons. Moreover, the NAcc has been closely associated with some locomotor and other neurobehavioral effects of cocaine ([@A18780R9]-[@A18780R11]). Dexmedetomidine has been shown to markedly attenuate cocaine-induced coronary and systemic vasoconstriction in dogs ([@A18780R12]) and it was found to be effective and safe in abolishing both the sympathoexcitatory and corresponding hemodynamic effects of cocaine in healthy cocaine-naive human subjects ([@A18780R13]). Whittington et al. ([@A18780R14]) speculated that dexmedetomidine may be potentially beneficial in controlling cocaine-induced central nervous system (CNS) excitotoxicity. These results suggest that the central sympatholytic and sedative properties of dexmedetomidine may make this drug a reasonable choice for acute cocaine poisoning treatment. There have been a number of case reports where other more traditional agents have failed, while dexmedetomidine has been successfully used to manage hypertension and CNS excitability from withdrawal of cocaine and opioids ([@A18780R15]). Recently, similar results have also been reviewed related to poisoning with illicit substances ([@A18780R16]).

The modulation of peripheral sympathetic activity by the CNS may involve various pathways, neurotransmitters and receptors. In addition to the α2-AR, the central imidazoline (I1) receptors, which are distributed throughout the CNS ([@A18780R17]-[@A18780R20]) and probably located in the nucleus reticularis lateralis of the medullary region, may also be involved in the central regulation of peripheral sympathetic activity. They could also act as a target of centrally-acting antihypertensives. Moxonidine is the prototype of such agents, and also has a low affinity for the α2-AR. These data suggest that moxonidine may offer an alternative supplementary treatment for acute cocaine poisoning.

2. Objectives {#sec105301}
=============

Previously we reported the effects of pretreatment with etomidate, ketamine, phenytoin and phenytoin/midazolam on acute, lethal cocaine toxicity ([@A18780R21]). Also recently we determined the effects of pretreatment with etomidate, ketamine, phenytoin, and phenytoin/midazolam on the same experimental model ([@A18780R22]). The objective of this study was to determine whether pre-treatment with dexmedetomidine, moxonidine and alpha-methyldopa could attenuate cocaine toxicity. Our hypotheses were that these pre-treatments would decrease the proportion of animals reaching the end point of irreversible toxicity and would prolong the survival of cocaine-poisoned mice. If pre-treatment attenuates cocaine neurotoxicity, further studies can be performed to determine whether these drugs are effective once toxicity is established. To the best of our knowledge, this is the first trial that compares the efficacy of these three medications on cocaine induced seizures and mortality in this experimental pre-treatment model.

3. Materials and Methods {#sec105306}
========================

3.1. General {#sec105302}
------------

The experimental study was designed to reach 80% power to detect a 30% difference in lethality, assuming a control group survival of 30%. Experiments were carried out on 100 mice weighing 25-30 g, which were divided to four groups, three experimental and one control (n = 25). All groups were selected by means of a randomized schedule. We used the simple random allocation strategy. The experimental procedures used in this study were approved by the Animal Bioethical Committee of Pamukkale University (01, 05, 2010; PAUHDEK-2010/002). The room temperature was maintained at 23 ± 1ºC, and the humidity was kept at 50 ± 5%. All experiments were conducted between 2 and 6 pm to minimize the circadian rhythm effect on the convulsion threshold. This research was conducted during January 2011.

3.2. Drugs {#sec105303}
----------

Dexmedetomidine (Precedex, Abbott Park, Illionis, U.S.A.), alpha-methyldopa (as a substance from Ibrahim Ethem, Istanbul, Turkey) and moxonidine (as a substance from Abbott Park, Illionis, USA) were used for this study. Mice (n = 25/group) were randomly assigned to one of four groups that received either normal saline solution, 40 µg/kg dexmedetomidine, 200 mg/kg alpha-methyldopa, or 4 mg/kg moxonidine. All drugs were intraperitoneally administered 10 minutes before the mice received cocaine hydrochloride (105 mg/kg).

3.3. Main Outcome Measurements {#sec105304}
------------------------------

The primary measured outcomes in this study were seizure activity and lethality. Seizure activity was defined as convulsions, which were characterized by popcorn jumping, tonic-clonic activity, or righting reflex loss. Lethality was defined as the development of agonal respiration, seizures lasting longer than eight minutes, or an inability to ambulate for up to 30 minutes after cocaine administration.

The measured secondary outcomes were the seizure frequency ratio and the time to seizure. All outcomes were recorded by a single blinded observer, who observed the animals for 30 minutes. All animals were sacrificed at the end of the 30-minute experiment.

3.4. Statistical Analysis {#sec105305}
-------------------------

Chi-square and Fisher's exact tests were used for comparisons when appropriate. A survival analysis was performed, and Kaplan-Meier survival curves were generated with a log rank. Results were considered statistically significant when P \< 0.05. Data were analyzed with the Statistical Package for Social Sciences (SPSS) for Windows, Version 17.0.

4. Results {#sec105307}
==========

We observed that 86% of the mice had seizures after receiving 105 mg/kg of cocaine. More specifically, 68% (n = 17) of the animals in the dexmedetomidine group, 84% (n = 21) of the alpha-methyldopa group, 92% (n = 23) of the moxonidine group and 100% (n = 25) of the control group showed evidence of seizure activity (P = 0.009). The ratio of animals with seizures was significantly lower in the dexmedetomidine (68%) group in comparison to the control (P = 0.004) ([Table 1](#tbl27024){ref-type="table"}).

Cocaine-induced lethality was observed in 12% (n = 3) of the dexmedetomidine group, 48% (n = 12) of the alpha-methyldopa group, 52% (n = 13) of the moxonidine group and 72% (n = 18) of the control group (P \< 0.001). Dexmedetomidine was more protective than the placebo in terms of lethality (P \< 0.001). Cocaine-induced lethality was lower than the control (72%) in the alpha-methyldopa (48%) and moxonidine (52%) groups ([Table 1](#tbl27024){ref-type="table"}).

[Figure 1](#fig20042){ref-type="fig"} shows that all treatments prolonged (but not significantly) the time to seizure relative to placebo-treated mice (P \> 0.05). In addition, the time to lethality was also significantly longer in the dexmedetomidine group ([Figure 2](#fig20043){ref-type="fig"}, P \< 0.001).

###### Distribution of Convulsions and Lethality Produced by Cocaine According to the Study Groups ^[a](#fn26044){ref-type="table-fn"}^

  Variables       Study Groups   P value ^[b](#fn26045){ref-type="table-fn"}^                        
  --------------- -------------- ---------------------------------------------- --------- ---------- ----------
  **Seizure**     21 (84)        23 (92)                                        17 (68)   25 (100)   0.009
  **Lethality**   12 (48)        13 (52)                                        3 (12)    18 (72)    \< 0.001

^a^ Data are presented as No. (%).

^b^ Values come from the chi-squared test.

^c^ Comes from Fisher exact test, values are less than 0.05 between dexmedetomidine and other medications in terms of lethality and seizure except for Alpha-Methyldopa in terms of lethality.

![Kaplan-Meier Plot for Time to Seizures for Each Treatment Group](ircmj-17-06-18780-i001){#fig20042}

![Kaplan-Meier Plot for Apparent Lethality for Each Treatment Group](ircmj-17-06-18780-i002){#fig20043}

5. Discussion {#sec105308}
=============

The present study demonstrated that pre-treatment with dexmedetomidine, alpha-methyldopa or moxonidine reduced seizure activity and lethality during acute cocaine toxicity. It is important to note that dexmedetomidine was the most protective of these compounds. This article was the first report about dexmedetomidine efficacy against cocaine-induced seizures and death. These results were partly compatible with the literature.

Unlike beta adrenergic antagonists and α2-AR antagonists, the α2-AR agonists were shown to decrease cocaine-dependent seizures and mortality ([@A18780R23], [@A18780R24]). Compatible with our study, Whittington et al. ([@A18780R14]) showed that dexmedetomidine increased the cocaine dose needed to induce seizure activity, and the extracellular dopamine concentration in the nucleus ambiguus. In contrast to Mirski et al. ([@A18780R25]) and Kubota et al. ([@A18780R26]) in this study we observed that dexmedetomidine reduced seizure activity. These results suggest that the central sympatholytic and sedative properties of dexmedetomidine may make this drug a reasonable choice for acute cocaine poisoning treatment. Thus there have been a number of case reports where other more traditional agents have failed, while dexmedetomidine has been successfully used to manage hypertension and CNS excitability from withdrawal of cocaine and opioids ([@A18780R15]). Recently, similar results have also been reviewed about poisoning with illicit ([@A18780R16]).

Cocaine-dependent seizures were related to the stimulation of dopamine 1 receptors, thus dopamine 1 receptor antagonists decreased cocaine-dependent mortality ([@A18780R27]). In addition, a similar study reported that dexmedetomidine has a sedative and analgesic effect ([@A18780R28]).

It was reported that in a case of a 45- year-old cocaine-dependent female patient, cocaine exposure conferred hypertension, which was decreased after dexmedetomidine (1 microgram/kg, 10 minutes) infusion, and mortality was avoided ([@A18780R15]). In another study, Kersten et al. ([@A18780R12]) reported that dexmedetomidine decreased morbidity and mortality related to cocaine toxicity. According to several studies based on the American Heart Association guidelines 2010, dexmedetomidine with its antihypertensive and bradycardic effects may be used to treat cocaine toxicity-related coronary syndrome instead of beta-adrenergic blocking drugs ([@A18780R29]-[@A18780R31]).

Moxonidine is a central sympatholytic, central imidazoline (1I) receptor agonist, α2-AR agonist, and antihypertensive drug ([@A18780R6]). Following a 1 mg/kg moxonidine injection into cocaine-dependent mice, there was a decrease in cocaine-related effects like locomotor activity without sedation ([@A18780R32]). Alpha-methyldopa was shown to produce peripheral sympatho inhibition and antihypertensive effects by acting on the α2-AR in the pons and medulla oblongata ([@A18780R33]). The side effects of alpha-methyldopa are greater than that of moxonidine in antihypertensive therapy. The sedative effect of alpha-methyldopa may ameliorate the agitation associated with cocaine toxicity.

Even though an accepted model was used in this study, we can only use these findings to support the safety and efficacy of these treatments for human studies. This study has a number of limitations. First, we could not determine whether there was any EEG evidence of ongoing seizures and epileptogenic activity (non-convulsive seizures) for logistical reasons. Thus, it is possible that some seizures may have been missed. Second, because no hemodynamic or electrocardiographic monitoring was carried out, the mechanism of death could not be determined. Third, it is possible that in some cases, cardio-respiratory arrest, death, and seizures were caused by the sedatives and were not related to cocaine intoxication. Last, even though this is an accepted model, there is a limitation related to the use of pre-treatment drugs with there being only one application route (i.e. injection).

In conclusion, the present study provides the first experimental evidence to support the use of dexmedetomidine for treating cocaine-induced toxicity. Premedication with dexmedetomidine reduced seizure activity during acute cocaine toxicity. In addition, dexmedetomidine seems to be effective in preventing cocaine-induced lethality. We suggest that further studies should be performed to evaluate the potential utility of dexmedetomidine for acute cocaine poisoning in humans.
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